Cheilonda Johnson

Cheilonda Johnson

Auto-generated profile, based on publicly available information

Cheilonda Johnson

University of Pennsylvania , Philadelphia, PA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2025 in Rheumatology
Verified
Journal Article
Closed access
RARohit Aggarwal
Rohit Aggarwal
NPNantakarn Pongtarakulpanit
Nantakarn Pongtarakulpanit
DSDaniel I Sullivan
Daniel I Sullivan
SMSiamak Moghadam-Kia
Siamak Moghadam-Kia
SBSangmee Sharon Bae
Sangmee Sharon Bae
COChester V Oddis
Chester V Oddis
Objectives: This randomized, placebo-controlled pilot trial evaluated the efficacy and safety of abatacept in patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD). Methods: Participants with active ASyS-ILD were randomized to receive abatacept (n = 9) or placebo (n = 11) for 24 weeks, followed by a 24-week open-label extension with abatacept for all participants. The primary endpoint was a change in % predicted forced vital capacity (%FVC) from baseline to week 24. Secondary endpoints included changes in the FVC (ml), % predicted diffusing capacity of the lung for carbon monoxide (%DLCO), shortness of breath questionnaire (SOBQ) and pulmonary disease activity on a visual analogue scale (VAS) at weeks 24 and 48. Pre-post baseline analysis of FVC and quantitative image analysis (QIA) of high-resolution computed tomographic scans were performed. Data were analysed using a generalized linear mixed model. The study was not powered for primary or secondary endpoints. Results: At week 24, there was no significant difference in the primary endpoint of %FVC change between abatacept and placebo (between treatment difference of −0.35, 95%CI −6.91 to 6.21, P = 0.914) and in all secondary endpoints. However, by week 48, trends favouring abatacept in %FVC, FVC (ml), %DLCO and SOBQ were observed without statistical significance. There was a significant improvement in pulmonary disease activity VAS and pre-post baseline slopes of %FVC and QIA scores in the abatacept arm. Abatacept was generally well tolerated. Conclusion: Abatacept did not significantly improve %FVC at 24 weeks. However, trends at 48 weeks suggest potential benefits, supporting the need for a larger, long-term randomized controlled trial. Clinical trial registration: clinicaltrials.gov; NCT03215927

1 March 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CJCheilonda Johnson
Cheilonda Johnson
ASAdam Schiffenbauer
Adam Schiffenbauer
JPJamie Perin
Jamie Perin
ADAvantika R. Diwadkar
Avantika R. Diwadkar
JJJaehyun Joo
Jaehyun Joo
MGMyositis-ILD Study Group
Myositis-ILD Study Group

6 April 2026 in Respiratory Medicine
Verified
Journal Article
Open access
MAMichaela R. Anderson
Michaela R. Anderson
MPMary K. Porteous
Mary K. Porteous
WHWen-Chi Hsu
Wen-Chi Hsu
CLCheng Ting Lin
Cheng Ting Lin
CJCheilonda Johnson
Cheilonda Johnson
Combined pulmonary fibrosis and emphysema (CPFE) is a well-recognized syndrome characterized by the coexistence of emphysema and fibrotic interstitial lung disease (ILD) and is associated with high mortality. However, the prognostic significance of emphysema extent relative to fibrosis pattern remains incompletely defined. We conducted an observational cohort study of participants with fibrotic ILD and radiographic emphysema. Baseline high-resolution computed tomography (HRCT) scans were independently assessed by two thoracic radiologists using a standardized semi-quantitative scoring system. Cox proportional hazards regression was used to evaluate associations between imaging features and all-cause mortality. Ninety-two participants with CPFE were followed for a median of 8 years, during which 70% died. Cumulative mortality was 4.4% at 1 year, 21.7% at 3 years, and 30.5% at 5 years. Most participants demonstrated a definite usual interstitial pneumonia pattern and centrilobular emphysema, with the majority having 5% emphysema had a significantly higher risk of death (HR 3.96, 95% CI 1.43-10.95; p = 0.008). Fibrosis pattern, emphysema subtype, and regional disease distribution were not independently associated with mortality. Semi-quantitative emphysema extent on HRCT is a strong, independent prognostic marker in CPFE. These findings support routine assessment of emphysema burden to inform risk stratification in CPFE.

1 October 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
CJCheilonda Johnson
Cheilonda Johnson
APAnna J. Podolanczuk
Anna J. Podolanczuk
SDSonye K. Danoff
Sonye K. Danoff
MKMary E. Kreider
Mary E. Kreider
MAMichaela R. Anderson
Michaela R. Anderson

1 January 2025 in South African Journal of Radiology
Verified
Journal Article
Open access
PDF file
WMWallace Miller
Wallace Miller
SSScott Simpson
Scott Simpson
SSShweta Sood
Shweta Sood
MHMichelle Hershman
Michelle Hershman
CJCheilonda R. Johnson
Cheilonda R. Johnson
KPKaren C. Patterson
Karen C. Patterson
Background: Evaluation of diffuse interstitial lung disease (ILD) in thoracic imaging is complicated. Radiologists often use a pattern approach to interpretation; however, they are rarely aware of the statistical frequency of disease presentation. Objectives: To evaluate the relative frequency of causes of fibrotic ILD as a function of imaging patterns. Method: A CT database of 396 cases of fibrotic ILD was amassed from an institutional diffuse lung disease registry and retrospective search of medical records. Three radiologists and one pulmonologist independently and blindly reviewed the CT scans for the distribution of fibrosis, predominant feature and non-pulmonary findings. Results: Peripheral fibrosis was most common (291/396, 73.5%), usually caused by idiopathic pulmonary fibrosis (IPF) and connective tissue diseases-related interstitial lung disease (CTD-ILD) but occasionally by hypersensitivity pneumonitis (HP), idiopathic nonspecific interstitial pneumonia (iNSIP) and asbestosis. Peripheral fibrosis with honeycombing was usually IPF and without honeycombing, was usually CTD-ILD. Peripheral fibrosis with pleural plaques was always asbestosis. Peripheral fibrosis with oesophageal dilatation was usually connective tissue diseases. Consolidative-like peripheral fibrosis was CTD-ILD. Axial fibrosis (61/396, 15.4%) was usually sarcoidosis, HP, CTD-ILD or silicosis. Axial fibrosis with predominantly consolidative-like fibrosis, honeycombing, or reticulation was usually sarcoidosis. Axial fibrosis predominated by ground glass opacity was usually HP or CTD-ILD. Lymph node calcification or short axis > 17 mm increased the probability that axial fibrosis was due to sarcoidosis. The non-specific fibrosis phenotype was uncommon (44/396, 11.1%), usually CTD-ILD (25/44, 57%) but also HP, IPF, iNSIP or asbestosis. Conclusion: Patterns of lung fibrosis provide guidelines to identify the cause. Contribution: A flow diagram that predicts the relative frequency of the causes of 10 patterns of ILD.

2 July 2026 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
KAKerri I Aronson
Kerri I Aronson
GHGregor Horvath
Gregor Horvath
RIRosalinda V Ignacio
Rosalinda V Ignacio
AHAnna Harris
Anna Harris
APAnna J Podolanczuk
Anna J Podolanczuk
MAMichaela R Anderson
Michaela R Anderson
Background: Obesity affects one third of patients with interstitial lung disease (ILD) and increases both fatigue and dyspnea in the general population. Fatigue and dyspnea are commonly reported by patients with ILD and are difficult to treat. We hypothesized that higher body mass index (BMI) would associate with greater fatigue and dyspnea, worse health-related quality of life (HRQoL), and greater changes in symptoms over time in a real-world ILD cohort. Methods: We performed a retrospective analysis of a cohort study of participants in the Pulmonary Fibrosis Foundation Registry with BMI and at least one questionnaire available at enrollment. Symptoms were assessed at enrollment, 6, and 12 months using the Fatigue Severity Scale, UCSD Shortness of Breath, and Short-Form Six-Dimension questionnaires. Linear mixed models with random intercept for participant and interaction between time and BMI evaluated whether BMI correlated with symptoms and changes in symptoms over time. We used random-intercept cross-lagged panel models to evaluate the reciprocal relationship between BMI and symptoms. All models were adjusted for baseline age; sex; ILD diagnosis, diabetes, hypertension, coronary artery disease, and depression diagnoses; use of antifibrotics and corticosteroids; use of supplemental oxygen, and pulmonary function, with forced vital capacity and diffusing capacity of the lung for carbon monoxide as time-varying covariates. Results: 1544 participants were included, 1029 (67%) had 12-month data, with mean (standard deviation) age of 68 (10.3) years, 35% were female, 63% had IPF, percent predicted forced vital capacity of 68% (18.1%), and BMI of 29 (5.8) kg/m2; 87% were using anti-fibrotic therapy at enrollment. Higher BMI was associated with greater fatigue and dyspnea but not with HRQoL. BMI did not moderate changes in fatigue (p-value = 0.29), dyspnea (p-value = 0.98), or HRQoL (p-value = 0.91) over time. BMI and fatigue had bidirectional associations over time wherein lower BMI was associated with greater subsequent symptoms, and greater symptoms were associated with lower subsequent BMI. Conclusion: Higher BMI is associated with greater fatigue and dyspnea on average in patients with ILD, independent of comorbidities and medications. Longitudinally, BMI did not moderate change in these symptoms over time. Further work should investigate whether intentional weight loss can improve fatigue and dyspnea in patients with obesity and ILD.